AL101 – PGRN – Neurodegenerative diseases

AL101 is designed to increase progranulin levels for the treatment of more prevalent neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. Mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of developing Alzheimer’s disease and Parkinson’s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models. 

AL101 is currently being studied in a Phase 1 clinical trial of healthy volunteers designed to assess safety, tolerability and pharmacokinetics and pharmacodynamics. AL101 is being developed in collaboration with GSK.